64Cu-SAR-bisPSMA (Clarity Pharmaceuticals): FDA status

Breakthrough designation Indication: PSMA PET imaging of prostate cancer in men with suspected biochemical recurrence based on elevated PSA. Company: Clarity Pharmaceuticals.

Regulatory history

All products in the FDA Tracker

Loading today's edition…